Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10382 vs Investigator-selected TKIs in Newly Diagnosed Ph+ CML-CP
NCT07885293Phase 3Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Dec 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 3 trial of TERN-701 in chronic myeloid leukemia (CML), sponsored by Hansoh Pharmaceutical Group. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
TERN-701
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT07885293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07885293.